1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Mercury Laboratories Ltd.

Mercury Laboratories Ltd.

BBSE:MERCURYLAB
730.00
INR
-10.00
(-1.35%)
34.69EPS
22.68P/E
944.04MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
345.41
343.26
395.98
400.23
432.23
462.67
477.24
571.68
482.7
627.78
629.66
625.84
632.81
614.48
Basic EPS, GAAP
26.85
27.61
32.69
22.53
16.78
23.63
26.9
44.48
29.68
46.49
47.12
26.21
40.28
34.69
Free Cash Flow per Basic Share
8.14
16.19
-3.13
3.51
10.43
1.94
36.26
29.95
27.29
11.63
16.28
-34.85
8.96
- -
Dividend per Share
1.74
1.74
1.81
1.81
1.81
1.81
1.81
3.5
2
3.5
3.5
3.5
3.5
- -
Book Value per Share
128.38
151.18
182.06
203.94
219.56
241.38
266.48
307.46
335.89
380.24
423.65
446.41
483.97
- -
Tangible Book Value per Share
128.38
151.18
181.73
202.61
218.89
240.78
266.11
306.76
335.42
379.9
423.44
446.19
483.92
- -
Basic Weighted Avg Shares
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Sales/Revenue/Turnover
414
412
475
480
519
555
573
686
579
753
756
751
759
738
Operating Margin (%)
13.77
13.39
11.13
11.99
5.67
7.38
7.79
13.44
8.25
8.76
10.14
9.87
7.4
6.2
Depreciation Expense
9
12
12
13
15
16
19
19
25
25
28
29
34
33
Net Income, GAAP
32
33
39
27
20
28
32
53
36
56
57
31
48
42
Effective Tax Rate (%)
32.79
28.05
20.53
44.77
18.02
29.98
25.43
32.51
29.25
25.06
18.3
32.54
27.17
24.04
Profit Margin (%)
7.77
8.04
8.26
5.63
3.88
5.11
5.64
7.78
6.15
7.41
7.48
4.19
6.37
5.64
Working Capital
13
22
111
150
167
150
164
190
195
253
272
241
333
- -
LT Debt
39
19
66
74
97
85
63
62
29
25
29
38
70
- -
Total Equity
154
181
218
245
263
290
320
369
403
456
508
536
581
- -
Return on Invested Capital (%)
- -
14.03
12.57
8.15
6.51
7.47
7.93
11.99
7.07
9.33
9.85
5.1
6.26
- -
Return on Capital (%)
- -
16.46
18.12
9.66
7.06
8.89
9.05
13.25
8.16
11.5
10.58
5.7
7.9
- -
Return on Common Equity (%)
- -
19.75
19.62
11.67
7.92
10.26
10.59
15.5
9.23
12.98
11.72
6.02
8.66
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
14
- -
LT Borrowings
- -
67
- -
LT Finance Leases
- -
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
973
840
944

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
449
- -
Cash, Cash Equivalents & STI
- -
55
- -
Accounts Receivable, Net
- -
258
- -
Inventories
- -
71
- -
Total Current Liabilities
- -
117
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
14
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.31%
9.53%
8.41%
Free Cash Flow
119.25%
-93.22%
-125.7%
Net Income, GAAP
9.74%
6.81%
53.71%
Sales/Revenue/Turnover
5.43%
3.06%
1.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
167
182
196
207
751
2026
181
190
184
204
759
2027
160
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
2.85
4.17
9.94
9.25
26.21
2026
8.06
13.69
8.31
10.21
40.28
2027
2.48
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3.5
2026
- -
- -
- -
- -
3.5
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Rajendra Ramanlal Shah
Full Time Employees
510
Sector
Health technology
Industry
Pharmaceuticals: major
Address
2/13-14, BIDC Gorwa Industrial Estate Vadodara GU India 390016
IPO Date
Feb 20, 2015
Website
mercurylabs.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Mercury Laboratories Limited (MERCURYLAB.BO), founded in 1962 and headquartered in Vadodara, Gujarat, India, manufactures, markets, exports and distributes pharmaceutical formulations primarily focused on mother and child healthcare, gynecology and pediatrics segments; its core products encompass tablets, oral liquids, small volume parenterals, ophthalmic and ear drops across therapy areas including analgesics, anti-inflammatories, anti-pyretics, anthelmintics, antibiotics, anti-coagulants, anti-platelets, haemostats, anti-fungals, anti-hypertensives, anti-malarials, cardiovascular, central nervous system, gastro-intestinal, hypoglycemics, multivitamins, protein supplements, respiratory, anti-allergics, steroids, urinary tract and uterine stimulants; the company operates state-of-the-art facilities spanning 435,600 square feet with separate units for tablets, liquids, injectables and ophthalmics, holding international accreditations such as WHO-GMP, NAFDAC Nigeria, FDA Ghana, DPML Ivory Coast, MoH Congo, CDDA Sri Lanka and MoH Cambodia, serving domestic and global markets in Africa, Asia and beyond. In recent developments, Mercury Laboratories reported standalone net profit surging 228% to Rs 1.64 crore for the quarter ended September 2025, with sales up 4.51% year-over-year to Rs 19.01 crore, alongside March 2025 net sales growth of 18.95% to Rs 20.66 crore, reflecting improved operational performance amid stable promoter holding of 73.66% and minimal debt.